Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited Listed on the ASX and Nasdaq under the ticker TLX. You are encouraged to report negative side effects of prescription drugs to the FDA.

Telix is a global biopharmaceutical company focused on developing and commercializing radiopharmaceuticals to address significant unmet medical need in oncology and rare diseases. Telix is a clinical-stage biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations

in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report adverse reactions to Telix by calling 1-844-455-8638 or emailing [email protected]. Please see full Illuccix Prescribing Information:https://illuccixhcp.com/wp-content/uploads/illuccix-prescribing-information.pdf

31/07/2026

Why does positron yield matter?

Positron yield is one of the key properties that differentiates PET radioisotopes, with implications for image quality, clinical workflow and the patient experience.

In this episode of Radiopharma Unpacked, nuclear medicine radiologist Dr. Umesh Oza explains why.

Watch the full episode here: https://youtu.be/vqTanq7bljg?si=Jp_A_QFTyVeBkjBk

27/07/2026

New treatments for glioblastoma is one of the greatest unmet needs in oncology. Despite decades of research, options remain limited, highlighting the urgent need for innovation.

Telix's investigational targeted radionuclide therapy, TLX101-Tx, is designed to cross the blood-brain barrier and deliver radiation directly to tumor cells by leveraging the LAT1 amino acid transport pathway. This novel therapy candidate is currently being evaluated in the Phase 3 IPAX BrIGHT study in patients with recurrent glioblastoma.

Thank you to Natasha Robinson and The Australian for highlighting the urgent need for innovation in brain cancer, and the researchers, clinicians, patient advocates and patients working to improve outcomes for people living with this devastating disease.

Read the article here (behind paywall): https://www.theaustralian.com.au/health/medical/glioblastoma-brain-cancer-fight-is-finally-on-the-crest-of-breakthrough/news-story/06b74dd15ee4b6e7e0c32a20a7b239fa

For more information on the Phase 3 IPAX BrIGHT study visit: https://clinicaltrials.telixpharma.com/trial/ipax-bright/

TLX101-Tx has not received marketing authorization in any jurisdiction.

22/07/2026

No two radioisotopes behave the same, and those differences can have important implications for PSMA-PET imaging and patient care.

Introducing Radiopharma Unpacked, a new series featuring expert insights into the science behind radiopharmaceuticals. In this edition, nuclear medicine radiologist Dr. Oza explores why isotope choice matters, from positron yield and half-life to radiation dose, scan duration and imaging performance.

Across Gallium-68, Fluorine-18 and Copper-64, Dr. Oza discusses how each isotope's characteristics can influence manufacturing and distribution, clinical workflow, and the patient experience.

Watch the explainer below to learn more about the science behind isotope selection in PSMA-PET imaging.

Read more about the future of prostate cancer imaging on our website here: https://telixpharma.com/news-views/psma-pet-imaging-for-prostate-cancer-exploring-gallium-68-in-clinical-practice/

20/07/2026

Telix has today provided a market update for Q2 2026, reporting unaudited Group revenue of approximately US$247 million, up 21% year-over-year.

This result reflects continued growth across the Precision Medicine business, with revenue of approximately US$202 million, up 30% year-over-year, driven by growing demand for both Illuccix® and Gozellix®.

The quarter also delivered continued progress across Telix’s investigational theranostic portfolio, including:

🔵 FDA alignment to advance Part 2 of the ProstACT® Global Phase 3 study of TLX591-Tx in the U.S. (prostate cancer therapy).

🔵 A strategic collaboration with Regeneron to jointly develop and commercialize next-generation radiopharmaceutical therapies, initially focused on lung cancer.

🔵 Acceptance of the Pixclara® (TLX101-Px) U.S. NDA resubmission, with a PDUFA goal date of September 11, 2026 (brain cancer imaging).

🔵 Continued advancement across the clinical pipeline, including first patients dosed and completion of patient enrollment in multiple late-stage studies across prostate, kidney and brain cancer.

Read the full announcement on our website here: https://telixpharma.com/news-views/telix-q2-2026-revenue-us247m-strong-momentum-and-pipeline-progress/

Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) has been approved by the FDA and in multiple markets globally. Gozellix® (kit for the preparation of gallium Ga 68 gozetotide injection) has been approved by the FDA. All other Telix products mentioned in this post are investigational products and have not received marketing authorization in any jurisdiction.

20/07/2026

The first patient has been dosed in the Phase 3 LUTEON study of investigational TLX250-Tx (lutetium (¹⁷⁷Lu) girentuximab tetraxetan) for patients with relapsed or recurrent clear cell renal cell carcinoma (ccRCC).

LUTEON is the first Phase 3 study evaluating a carbonic anhydrase IX (CAIX)-targeted radiopharmaceutical therapy in this disease setting.

ccRCC is the most common and often the most aggressive form of kidney cancer. Despite advances in treatment, outcomes remain poor for many patients, highlighting the need for new therapeutic approaches.

Congratulations to Dr. Aviral Singh and the team at GenesisCare Murdoch on dosing the first patient, and thank you to the patients participating in this important clinical research.

Read more here: https://lnkd.in/eH2eSJSn

ClinicalTrials.gov ID: NCT07197580.

TLX250-Tx is an investigational product and has not received marketing authorization in any jurisdiction.

20/07/2026

The first patient has been dosed in the Phase 3 LUTEON study of investigational TLX250-Tx (lutetium (¹⁷⁷Lu) girentuximab tetraxetan) for patients with relapsed or recurrent clear cell renal cell carcinoma (ccRCC).

LUTEON is the first Phase 3 study evaluating a carbonic anhydrase IX (CAIX)-targeted radiopharmaceutical therapy in this disease setting.

ccRCC is the most common and often the most aggressive form of kidney cancer. Despite advances in treatment, outcomes remain poor for many patients, highlighting the need for new therapeutic approaches.

Congratulations to Dr. Aviral Singh and the team at GenesisCare Murdoch on dosing the first patient, and thank you to the patients participating in this important clinical research.

Read more here: https://telixpharma.com/news-views/telix-doses-first-patient-in-phase-3-luteon-trial-of-tlx250-txfor-renal-cancer/

ClinicalTrials.gov ID: NCT07197580.

TLX250-Tx is an investigational product and has not received marketing authorization in any jurisdiction.

16/07/2026

Enrollment is now complete in the pivotal Phase 3 registration study of TLX591-Px (Illuccix®, kit for the preparation of 68Ga-PSMA-11) for prostate cancer imaging in Japan.

This milestone supports Telix's registration strategy for Illuccix in one of the world's largest nuclear medicine markets and marks another step toward expanding access to PSMA-PET imaging globally.

Thank you to the patients, investigators and study teams whose commitment made this achievement possible in such a short time.

Learn more: https://telixpharma.com/news-views/telix-completes-patient-enrollment-in-tlx591-px-illuccix-japan-phase-3-study/

Illuccix has been approved in multiple markets globally, excluding in Japan where use is investigational only.

16/07/2026

From research and development to patient care, all under one roof.

Today's opening of Telix Manufacturing Solutions North Melbourne (TMSNM) marks another milestone in the expansion of Telix's global manufacturing network. This first-of-its-kind Australian radiopharmaceutical facility brings together research, manufacturing, imaging and patient dosing at a single site.

Developed in collaboration with the Melbourne Theranostic Innovation Centre (MTIC), the facility is designed to accelerate clinical development, strengthen sovereign manufacturing capability and help bring innovative radiopharmaceuticals to patients faster.

Read more on our website here: https://telixpharma.com/news-views/telix-opens-australian-first-facility-to-accelerate-delivery-of-new-cancer-treatments-and-expand-sovereign-manufacturing/

15/07/2026

The first patients have been dosed in the OPTIMAL-e Phase 2 study of Telix's investigational prostate cancer therapeutic, TLX597-Tx, designed to evaluate the potential of PSMA-targeted radioligand therapy in earlier-stage metastatic prostate cancer.

Building on the recently completed OPTIMAL-PSMA study, OPTIMAL-e will evaluate adaptive-dosed TLX597-Tx in combination with standard hormone therapies for patients with metastatic hormone-sensitive prostate cancer, with the goal of improving treatment response while maintaining quality of life.

Congratulations to Professor Louise Emmett and the team at St Vincent's Hospital Sydney, and thank you to the patients participating in this important research.

Thank you to Channel 9 National News for highlighting this important milestone for patients.

Read more on our website here: https://telixpharma.com/news-views/first-patients-dosed-in-optimal-e-trial-for-earlier-stage-prostate-cancer/

TLX597-Tx is an investigational product and has not received marketing authorization in any jurisdiction.

Address

55 Flemington Road, North
Melbourne, VIC
3051

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Telix Pharmaceuticals Limited posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category